Please login to the form below

Not currently logged in
Email:
Password:

Diagnostic breath-test analysis developed

Oxford Medical Diagnostics has developed a technology that enables diagnostics for various illnesses through breath analysis

Oxford Medical Diagnostics (OMD), which was formed in August 2010, has developed a unique technology that enables rapid, accurate and low-cost diagnostics for various illnesses, including diabetes, through breath analysis.

The company is currently prototyping a non-invasive point-of-care (at patient) diagnostic instrument to detect diabetes types 1 and 2, through identifying acetone in the breath. There are currently no major direct competitors in this area, while alternative methods include blood analysis which can be both painful and inconvenient.

The company's management team includes the CEO, Dr Tony Marchington, who founded Oxford Molecular, which reached an FTSE 250 valuation of £475m. This spin-off counts as one of the most successful entities linked to the University of Oxford and its intellectual property company, Isis Innovation.

OMD maintains close links with the University of Oxford and academics around the world, while it holds three important patents in plasma emission spectroscopy (PES – spectral analysis of light generated from a gaseous sample through which a small electric arc is passed) and exclusive licences to two further major patents through the University of Oxford.

10th January 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics